Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R…. BMJ 2021

Document identifier
CEI-BR-082
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA
Title
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Source
BMJ
Year
2021
Volume, issue, pages
372:n71
Digital object identifier
10.1136/bmj.n71
PubMed identifier
33782057
Record type
Journal article
Institute identifier
CEI-BR-082

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaxCompound monograph
Monograph: SelankCompound monograph
Monograph: DSIPCompound monograph
Monograph: EpithalonCompound monograph
Monograph: Thymosin alpha-1Compound monograph
Monograph: ThymalinCompound monograph
Monograph: SS-31 (elamipretide)Compound monograph
Monograph: Kisspeptin-10Compound monograph
Monograph: GonadorelinCompound monograph
Synthesis: Thymosin alpha-1 in immune modulation and adjunctive immunotherapy…Evidence synthesis
Synthesis: Gonadorelin in growth hormone deficiency and growth-hormone…Evidence synthesis
Synthesis: Kisspeptin-10 in growth hormone deficiency and growth-hormone…Evidence synthesis
Synthesis: Semax in cognitive performance and neuroprotection: effect on the…Evidence synthesis
Synthesis: SS-31 (elamipretide) in primary mitochondrial myopathy and…Evidence synthesis
Synthesis: Thymosin alpha-1 in immune modulation and adjunctive immunotherapy…Evidence synthesis
Synthesis: Gonadorelin in growth hormone deficiency and growth-hormone…Evidence synthesis
Synthesis: Kisspeptin-10 in growth hormone deficiency and growth-hormone…Evidence synthesis
Synthesis: Semax in cognitive performance and neuroprotection: tolerability and…Evidence synthesis
Synthesis: SS-31 (elamipretide) in primary mitochondrial myopathy and…Evidence synthesis
Synthesis: Thymosin alpha-1 in immune modulation and adjunctive immunotherapy…Evidence synthesis
20 citing documents.

§1.3Subject tags

prisma methodology

Compound Evidence Institute · CEI-BR-082 · https://compoundevidence.com/bibliography/page2021/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.